Factor VII DeficiencyPhase 2NCT07711158
A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII Deficiency
A Phase 2 study testing SR604 in people with Factor VII Deficiency, run by Shanghai RAAS Blood Products Co., Ltd. at 1 site in China.
Trial summary
This is an open-label, multicenter, exploratory Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of SR604 Injection in patients with congenital coagulation Factor VII deficiency. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Factor VII Deficiency
- What is being tested?
- SR604
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteChina
- Study dates
- Jul 2026to Dec 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥12 years and ≤65 years at the time of signing the informed consent form; both genders eligible;
- Clinically diagnosed with congenital coagulation Factor VII deficiency, with historical or screening FVII activity <10%, and ≥2 treated new-onset bleeding events within 3 months prior to enrollment;
- No active bleeding symptoms prior to first administration of SR604 Injection;
- The subject and/or legal representative and impartial witness have signed the informed consent form, indicating voluntary agreement to participate in this trial, to provide biological samples for testing as required by the protocol, and to comply with the planned study visits;
- Female subjects (post-menarche) must have a negative serum pregnancy test (HCG) during the screening period; subjects with childbearing potential (females post-menarche or males post-spermarche) must agree to use highly effective contraceptive measures throughout the study period.
Who cannot join
- Known history of hypersensitivity to the study drug formulation or any of its components;
- Intolerance to subcutaneous injection or other local skin abnormalities or dermatoses that may affect drug administration or safety assessment;
- Meeting any one of the following criteria during screening:
- Hemoglobin <60 g/L;
- Platelet count <100×10⁹/L;
- Abnormal hepatic or renal function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.5× upper limit of normal (ULN), or total bilirubin ≥1.5× ULN; or serum creatinine (Cr) ≥1.5× ULN;
Show all 21Show fewer
- Positive for anti-human immunodeficiency virus (HIV) antibodies.
- Any bleeding disorder other than congenital Factor VII deficiency, or other conditions causing significantly abnormal coagulation parameters (e.g., hemophilia A or B, von Willebrand disease, platelet disorders, vitamin K deficiency, etc.);
- Protein C deficiency or Protein S deficiency;
- History of thrombosis, family history of thrombosis, or history of thrombophilia;
- Intracranial hemorrhage within 2 years prior to signing the informed consent form;
- Severe cardiac disease, such as unstable angina, congestive heart failure (New York Heart Association class ≥III), serious arrhythmia (QTc interval >450 ms, corrected by Fridericia formula), uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg), etc.;
- Female patients with menstrual abnormalities caused by organic gynecological conditions (e.g., uterine fibroids, endometriosis, adenomyosis, etc.);
- Received Factor VII-containing products within 48 hours prior to first administration of SR604 Injection; received whole blood or plasma transfusion within 2 weeks prior to first administration of SR604 Injection;
- Used any anticoagulants, antifibrinolytics, or agents affecting platelet function (including chemical drugs, biological products, or traditional Chinese medicine), including aspirin, within 1 week prior to screening, or required use of such agents during the treatment period;
- Underwent major surgery (defined as Grade III or IV surgery) within 1 month prior to signing the informed consent form, or planned to undergo surgery during the study period;
- Enrolled in other clinical trials within 1 month prior to signing the informed consent form;
- Miscarriage or pregnancy termination within 3 months prior to signing the informed consent form; pregnant or breastfeeding women;
- Mental illness or significant psychiatric disorder, or incapacity or lack of cognitive ability due to other causes;
- Other conditions deemed by the investigator to be unsuitable for enrollment, such as alcoholism, anticipated poor subject compliance preventing completion of dosing and study follow-up, poorly controlled comorbid chronic diseases, or serious systemic diseases.
- -
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin
About this study
Official title: An Open-Label, Multicenter, Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of SR604 Injection in Patients With Congenital Coagulation Factor VII Deficiency
This is an open-label, multicenter, exploratory Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of SR604 Injection in patients with congenital coagulation Factor VII deficiency.
- Conditions
- Factor VII Deficiency
- Being tested
- SR604
- Medical subject headings
- Factor VII Deficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SR604Drug
SR604 will be administered as SC injection.
| Study group | Role | What they receive |
|---|---|---|
| SR604：Multiple-dose exploratory efficacy trial consists of 2 cohorts | Experimental | Participants with FVII deficiency will receive SR604 dose 1/2 as multiple SC injections every 4-weeks Receives: Drug: SR604 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Treated overall Annualized Bleeding Rate (ABR)
Measured: Through 28 weeks of treatment.
Secondary outcomes (8)
Treated spontaneous annualized bleeding rate
Measured: over 28 weeks of treatment
Treated overall annualized joint bleeding rate
Measured: over 28 weeks of treatment
Overall annualized bleeding rate including treated and untreated bleeding events
Measured: over 28 weeks of treatment,
Annualized menorrhagia bleeding rate (menstruating females only)
Measured: over 28 weeks of treatment
Change in PBAC score (menstruating females only);
Measured: From baseline over 28 weeks of treatment
Change in EQ-5D-5L health index score
Measured: From pre-treatment over 28 weeks of treatment
Change in EQ-VAS score
Measured: From baseline over 28 weeks of treatment;
Subject overall satisfaction score with treatment efficacy
Measured: over 28 weeks of treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2026
- Study startJul 2026 (estimated)
- Primary completionFeb 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Factor VII DeficiencyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai RAAS Blood Products Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07711158
- Sponsor's protocol ID
- LS-SR604-VII-II01
- Status last verified
- May 2026
- First submitted
- 14 Jul 2026
- Last updated
- 17 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label, Multicenter, Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of SR604 Injection in Patients With Congenital Coagulation Factor VII Deficiency
- ClinicalTrials.gov ID
- NCT07711158
- Acronym / sponsor ID
- LS-SR604-VII-II01
- Conditions
- Factor VII Deficiency
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- Shanghai RAAS Blood Products Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- Jul 2026 (estimated)
- Primary completion
- Feb 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 17 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an open-label, multicenter, exploratory Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of SR604 Injection in patients with congenital coagulation Factor VII deficiency.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| SR604：Multiple-dose exploratory efficacy trial consists of 2 cohorts | Experimental | Drug: SR604Participants with FVII deficiency will receive SR604 dose 1/2 as multiple SC injections every 4-weeks |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥12 years and ≤65 years at the time of signing the informed consent form; both genders eligible;
- Clinically diagnosed with congenital coagulation Factor VII deficiency, with historical or screening FVII activity <10%, and ≥2 treated new-onset bleeding events within 3 months prior to enrollment;
- No active bleeding symptoms prior to first administration of SR604 Injection;
- The subject and/or legal representative and impartial witness have signed the informed consent form, indicating voluntary agreement to participate in this trial, to provide biological samples for testing as required by the protocol, and to comply with the planned study visits;
- Female subjects (post-menarche) must have a negative serum pregnancy test (HCG) during the screening period; subjects with childbearing potential (females post-menarche or males post-spermarche) must agree to use highly effective contraceptive measures throughout the study period.
Key exclusion criteria (21 listed)
- Known history of hypersensitivity to the study drug formulation or any of its components;
- Intolerance to subcutaneous injection or other local skin abnormalities or dermatoses that may affect drug administration or safety assessment;
- Meeting any one of the following criteria during screening:
- Any bleeding disorder other than congenital Factor VII deficiency, or other conditions causing significantly abnormal coagulation parameters (e.g., hemophilia A or B, von Willebrand disease, platelet disorders, vitamin K deficiency, etc.);
- Protein C deficiency or Protein S deficiency;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SR604SR604 will be administered as SC injection. | Drug | SR604：Multiple-dose exploratory efficacy trial consists of 2 cohorts |
Primary outcome
Treated overall Annualized Bleeding Rate (ABR)
Time frame: Through 28 weeks of treatment.
8 secondary outcomes
Treated spontaneous annualized bleeding rate
Time frame: over 28 weeks of treatment
Treated overall annualized joint bleeding rate
Time frame: over 28 weeks of treatment
Overall annualized bleeding rate including treated and untreated bleeding events
Time frame: over 28 weeks of treatment,
Annualized menorrhagia bleeding rate (menstruating females only)
Time frame: over 28 weeks of treatment
Change in PBAC score (menstruating females only);
Time frame: From baseline over 28 weeks of treatment
Change in EQ-5D-5L health index score
Time frame: From pre-treatment over 28 weeks of treatment
Change in EQ-VAS score
Time frame: From baseline over 28 weeks of treatment;
Subject overall satisfaction score with treatment efficacy
Time frame: over 28 weeks of treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Factor VII Deficiency
RecruitingPhase 2
A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency
Congenital Factor VII Deficiency
RecruitingPhase 1
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Healthy Participants, Hemophilia A
Active, not recruitingObservational study
Early Check: Expanded Screening in Newborns
Spinal Muscular Atrophy, Fragile X Syndrome
RecruitingPhase 1/2
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
Hemophilia A, Hemophilia B
Enrolling by invitation
Palliative Care Needs of Children With Rare Diseases and Their Families
Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing SR604 in people with Factor VII Deficiency, run by Shanghai RAAS Blood Products Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Research and Development (862122130888, hanyu@raas-corp.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treated overall Annualized Bleeding Rate (ABR) (time frame: Through 28 weeks of treatment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.